HCWB
NASDAQHCW Biologics Inc.
News25/Ratings1
News · 26 weeks64+14%
2026-03-012026-08-23
Mix3390d
- SEC Filings18(55%)
- Other8(24%)
- Insider6(18%)
- Dividends1(3%)
Latest news
25 items- PRHCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased CellsHuman studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8+ T cells and NK cells Company has incorporated the TGF-β/IL-15 moiety into the constructs of its second-generation fusion immunotherapeutics constructed with novel TRBC drug development platform MIRAMAR, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, together with collaborators at leading research institutions, have identified a TGF-β trap and I
- SECSEC Form S-1 filed by HCW Biologics Inc.S-1 - HCW Biologics Inc. (0001828673) (Filer)
- SECSEC Form 10-Q filed by HCW Biologics Inc.10-Q - HCW Biologics Inc. (0001828673) (Filer)
- SECHCW Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - HCW Biologics Inc. (0001828673) (Filer)
- PRHCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial ResultsMIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three and six months ended June 30, 2026. On June 16, 2026, the Company announced its preliminary human data readout for the first two cohorts in a dose-escalating Phase 1 clinical study to evaluate HCW9302 as a monotherapy in patients with alopecia areata. HCW9302 is a fusion immunotherapeutic which is potentially a best-in-
- SECAmendment: SEC Form 10-Q/A filed by HCW Biologics Inc.10-Q/A - HCW Biologics Inc. (0001828673) (Filer)
- SECHCW Biologics Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review8-K - HCW Biologics Inc. (0001828673) (Filer)
- SECSEC Form D filed by HCW Biologics Inc.D - HCW Biologics Inc. (0001828673) (Filer)
- INSIDERChief Executive Officer Wong Hing C bought $59,998 worth of shares (23,210 units at $2.58), increasing direct ownership by 23% to 125,845 units (SEC Form 4)4 - HCW Biologics Inc. (0001828673) (Issuer)
- INSIDERSVP of Business Development Flowers Lee bought $19,998 worth of shares (7,736 units at $2.58), increasing direct ownership by 810% to 8,691 units (SEC Form 4)4 - HCW Biologics Inc. (0001828673) (Issuer)
- INSIDERDirector Garrett Scott T bought $19,998 worth of shares (7,736 units at $2.58) (SEC Form 4)4 - HCW Biologics Inc. (0001828673) (Issuer)
- SECHCW Biologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - HCW Biologics Inc. (0001828673) (Filer)
- PRHCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement OfferingMIRAMAR, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today announced the pricing of its $1.6 million private placement offering (the "Offering") with a group of investors, including officers, directors and an existing stockholder of the Company, (each, and "Investor" and collectively, the "Investors"). Pursuant to a securities purchase agreement entered into with the Investors (the "Purchase Agreement"), the Company agreed to issue and sell an aggregate of 61
- PRHCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027Company requested Type B pre-IND meeting with U.S. FDA to discuss development and regulatory strategy for its investigational tetravalent T-cell engager, HCW11-018b HCW11-018b has demonstrated potential for treating solid tumors that overexpress human tissue factor, including gynecologic and pancreatic cancers Company has developed a streamlined, robust manufacturing process designed to produce high-quality cGMP material at a lower cost than current methods MIRAMAR, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat
- SECSEC Form POS AM filed by HCW Biologics Inc.POS AM - HCW Biologics Inc. (0001828673) (Filer)
- SECHCW Biologics Inc. filed SEC Form 8-K: Other Events8-K - HCW Biologics Inc. (0001828673) (Filer)
- SECHCW Biologics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - HCW Biologics Inc. (0001828673) (Filer)
- PRHCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance LetterMIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, today reported that, on June 29, 2026, the Nasdaq Hearings Panel (the "Panel") of The Nasdaq Stock Market LLC ("Nasdaq" or the "Exchange") found that the Company regained compliance with Listing Rule 5550(a)(2), the "Bid Price Rule," per the terms set forth in the Panel’s decision letter dated May 29
- SECHCW Biologics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - HCW Biologics Inc. (0001828673) (Filer)
- PRHCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock split effectuated to ensure ongoing compliance with the Bid Price Rule and additional requirements from Nasdaq Hearings Panel MIRAMAR, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, today announced that its Board of Directors has approved a 1-for-6 revers
- SECSEC Form EFFECT filed by HCW Biologics Inc.EFFECT - HCW Biologics Inc. (0001828673) (Filer)
- SECAmendment: SEC Form S-1/A filed by HCW Biologics Inc.S-1/A - HCW Biologics Inc. (0001828673) (Filer)
- SECHCW Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - HCW Biologics Inc. (0001828673) (Filer)
- PRHCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia AreataPotentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells Readout for dose-escalating clinical study for first two dose cohorts All participants in second dose cohort at the dose level of 3 micrograms/kg body weight showed positive clinical response after single dose administration Well tolerated, with no dose-limiting toxicities or significant known IL-2-treatment-related adverse effects, including no reported incidence of capillary leak, cytokine release syndrome, or increase in blood eosinophil counts HCW Biologics projects to establish the Recommended Phase 2 Dose by year end 2026 MIRAMAR, Fla., June 16, 2026 (GLOBE NEWSW
- SECHCW Biologics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - HCW Biologics Inc. (0001828673) (Filer)
HCWB FAQ
6 questionsWhere does HCWB stock trade?
HCW Biologics Inc. (HCWB) is listed on NASDAQ.What sector and industry is HCWB in?
HCW Biologics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did HCW Biologics Inc. go public?
HCW Biologics Inc. (HCWB) completed its IPO in 2021.What are analysts saying about HCWB?
HCW Biologics Inc. has had 1 recent analyst action on file. The most recent action was from EF Hutton: Buy with a $1000.00 price target on 2021-11-19. Recent price targets cluster around $1000.00.What companies are similar to HCWB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare HCWB side-by-side with any of them on Quantisnow.How can I track HCWB on Quantisnow?
Quantisnow aggregates HCW Biologics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HCWB to receive live email and push alerts on every new disclosure.